IL1RAPL1 and neoplasm: For example, MRX34, a miR-34 mimic encapsulated in a lipid carrier (developed by Mirna Therapeutics), has the advantage to become positively charged in the acidic tumor microenvironment, which allows the adherence of MRX34 specifically to tumor cells [151].